1. Introduction {#sec0005}
===============

Lead (Pb) is a non essential toxic heavy metal and one of the most widely used metal in industries. Pb may be found in printing, rubber, batteries, ceramics, dye, porcelain manufacturing, in accumulator industry and as a gasoline additive. Especially, the workers of these industrial branches are exposed to Pb [@bib0050], [@bib0215]. In addition, the general population may getting exposed to Pb by contaminated food and water and by air pollution caused by industrial emission [@bib0200], [@bib0225]. Unfortunately, even small quantities of Pb in the organism may are harmful [@bib0025], [@bib0210].

The main body structures affect by Pb exposure includes erythrocytes, liver and kidney [@bib0230]. The erythrocytes have a high affinity for Pb and contain about 99% of the Pb present in the blood, which they can spread to different organs of the body [@bib0305]. Liver, organ responsible for maintaining the body's metabolic homeostasis, has been considered as the target organ for the toxic effects of Pb [@bib0240] and the largest Pb repository of softy tissues followed by kidney [@bib0140], [@bib0245]. It has been known that Pb accumulation in these structures can interfere with several bioelements, whole role is critical for physiological processes.

Actually, Pb toxicity is related with oxidative stress (OS), due the capacity of Pb in disturbance the oxidant and antioxidant balance that is found in cells [@bib0195]. Lipids, proteins and carbohydrates can be oxidized by reactive oxygen species (ROS) in OS situations [@bib0120], [@bib0300]. To minimize the potential damages caused by OS, the body has a combination of antioxidants [@bib0205], which can be enzymatic \[e.g. superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase, and glutathione reductase\] or non-enzymatic \[e.g., non-protein thiol groups, reduzed glutathione (GSH) and vitamin C (VIT C) e E\] [@bib0110]. Several studies had showed increase in oxidative damages parameters, like lipid peroxidation and protein oxidation, as well as decrease in antioxidant defenses, like CAT, SOD, GSH and ascorbic acid, in blood/tissues of Pb-exposed animals [@bib0045], [@bib0065], [@bib0075], [@bib0155], [@bib0160], [@bib0170], [@bib0230], [@bib0265], [@bib0320]. In these studies, antioxidants have been designed to mitigate Pb-induced toxicity.

The current therapeutic approved to Pb intoxications is realized with chelation agents [@bib0010], like calcium disodium ethylenediamine tetraacetic acid (EDTA), 2,3-dimercaptopropanol (British Anti Lewisite, BAL) or meso 2,3-dimercaptosuccinic acid (DMSA), which increase the body excretion of Pb preventing the damages induced by this metal. However these compounds have a toxic potential in themselves [@bib0095] and cannot be used at therapeutically adequate dose for a prolonged period of time [@bib0080].

Gallic acid (3,4,5-trihydroxybenzoic acid, GA) ([Fig. 1](#fig0005){ref-type="fig"}) is a natural phenolic antioxidant extractable from plants, especially green tea [@bib0165], and is widely used in foods, drugs, and cosmetics. It received much attention because of its antioxidant actions and potent property of scavenge ROS, like superoxide anions, hydrogen peroxide, hydroxyl radicals and hypochlorous acid [@bib0260], [@bib0130], [@bib0255], attenuating OS. In our previous study, gallic acid showed protective action against locomotor damage and brain OS induced by Pb in rats [@bib0265], and against reserpine toxicity [@bib0270]. In this sense, the present study investigated the effect of GA in biochemical parameters of toxicity in blood, liver and kidney of Pb-treated rats.Fig. 1Chemical structure of gallic acid (3,4,5-trihydroxybenzoic acid).Fig. 1

2. Materials and methods {#sec0010}
========================

2.1. Drugs {#sec0015}
----------

Drugs were purchased from Merck (Darmstadt, Germany). Pb and EDTA were dissolved in saline and protected from light until the use time. GA was dissolved in ultra-pure water and used until 10 min after preparation, thus ensuring its properties. All other chemicals and solvents used were of analytical or pharmaceutical and used as received.

2.2. Animals {#sec0020}
------------

The experiment was conducted with 32 male Wistar rats weighing 240 ± 10 g (about 2-month-old) at the start of the experiment. Groups of three or four animals were kept in plexiglas cages with free access to food and water in a room with controlled temperature (22--23 °C) and in 12 h light/dark cycles with lights on at 7:00 am The number of animals used was the minimum to obtain relevant results. The experimental protocol was approved by the ethical commission for animal use of Federal University of Santa Maria (process number 109/2010), which is in accordance with the international norms of animal care and maintenance. Animals were used after 7 days of acclimation.

2.3. Experimental design {#sec0025}
------------------------

The animals were treated with saline (1 mL/Kg, i.p., n = 14) or Pb (50 mg/Kg i.p., n = 21) once a day (9 a.m.) for 5 consecutive days [@bib0230]. From day 6, the saline-treated animals received water (1 mL/Kg, twice a day) or GA (6,75 mg/Kg/mL, twice a day) by gavage for 3 consecutive days. In addition, the Pb-treated animals received water (1 mL/Kg, twice a day, p.o.), GA (6,75 mg/Kg/mL, twice a day, p.o.) or EDTA (55 mg/Kg/mL, twice a day, i.p.) for 3 consecutive days at 9 a.m. and 5 p.m. Thus, the experimental groups of the present study were: control (C group, n = 7), GA group (n = 7), Pb group (n = 6), Pb-GA group (n = 6), Pb-EDTA group (n = 6). GA and EDTA treatments were in according with methodology described by Reckziegel et al. [@bib0265].

Body weight variation of animals was monitored during the whole course of the experiment and they were expressed in% based on the weight recorded on the first day. The animals were sacrificed 15 h after the last dose under anesthesia with thiopental (50 mg/Kg body weight, i.p.) and euthanized by exsanguinations. Blood was collected by cardiac puncture and used to hematocrit and ALA-D activity and the remaining were centrifuged at 3000 rpm for 15 min to obtained plasma and erythrocytes, whose were also used for biochemical assays. The liver and kidney were removed and one part was stored at −20 °C for Pb quantification and the remaining were homogenized in 10 vols (w/v) of 0.1 M Tris-HCl buffer, pH 7.4, centrifuged at 3000 rpm for 10 min and the supernatants used for biochemical assays.

2.4. Biochemical assays {#sec0030}
-----------------------

Lipid peroxidation was measured by TBARS levels in tissues [@bib0220] and in plasma and erythrocytes [@bib0125], [@bib0145]. Results of TBARS were expressed as nmol MDA/g tissue, nmol MDA/mL plasma or nmol MDA/mL erythrocytes. Protein oxidation was determined by protein carbonyl levels [@bib0325]. Total carbonylation was calculated using a molar extinction coefficient of 22,000 M^−1^ cm^−1^, according Levine et al. [@bib0150] and the results were expressed as nmol protein carbonyl/g tissue. The blood ALA-D activity was assayed according to Berlin and Schaller [@bib0030] and the results were expressed as nmol PBG (porphobilinogen)/h/mL blood. Plasma transaminases \[alanine transaminase (ALT) and aspartate transaminase (AST)\] were measured according to Reitman and Frankel [@bib0275] and Bessey et al. [@bib0040] and expressed as UI/L.

Antioxidant enzymatic defenses evaluated in the present study were SOD [@bib0190] and CAT [@bib0005]. SOD results were expressed as Units (U)/g tissue (1U = amount of enzyme required to produce 50% inhibition at 40 °C) and CAT activity as μmol H~2~O~2~/min/mL erythrocytes or μmol H~2~O~2~/min/g tissue. In addition, non enzymatic antioxidants measured were GSH levels in tissues and erythrocytes [@bib0055], [@bib0125] and VIT C levels in plasma [@bib0090], [@bib0125]. The results of GSH levels were expressed as μmol GSH/g tissue or nmol GSH/mL erythrocytes and of VIT C as μg VIT C/mL plasma.

For Pb quantification, wet tissue weight and blood volume were recorded. According to Mesko et al. [@bib0180], after sample digestion with concentrated nitric acid using a microwave-assisted digestion system (Model Multiwave 3000, Anton Paar, Austria), digests were diluted to a constant volume with ultra pure water (Millipore, Billerica, USA). Determination Pb content was performed following the procedure of Peixoto et al. [@bib0250] with some modifications, using inductively coupled plasma optical emission spectrometer (ICP OES, Spectro Analytical Instruments, Model Spectro Ciros CCD, Germany) for tissues and inductively coupled plasma mass spectrometer (ICP-MS, PerkinElmer-SCIEX, Model Elan DRC II, Thornhill, Canada) equipped with a concentric nebulizer (Meinhard Associates, Golden, USA), a baffled cyclonic spray chamber (Glass Expansion, Inc., West Merbourne, Australia) and a quartz torch with a quartz injector tube (2 mm i.d.) for blood. The calibration standards were prepared from a multielemental standard solution by sequential dilution in 5% nitric acid in the range of 0.025--10 μg/L. The Pb detection limit was 0.2 ppm.

2.5. Statistical analysis {#sec0035}
-------------------------

Data were analyzed by one-way ANOVA, followed by Duncan's multiple range test when appropriate. Probability less than 0.05 were considered as statistically significant. Values were expressed as mean ± S.E.M.

3. Results {#sec0040}
==========

*The effects of Pb exposure and GA and EDTA treatments on the variation (gain/loss) of body weight are show in* [Table 1](#tbl0005){ref-type="table"}. Pb exposure decreased the body weight when compared to control group in sixth (end Pb exposure) and ninth (end treatment) days of protocol \[F(4,30) = 52.87 and F(4,30) = 30.00, respectively; *P* \< 0.001\]. The GA, but no EDTA, was able to reverse partially this alteration in the ninth day.Table 1Body weight variation of rats exposed to Pb (50 mg/Kg, i.p., daily) or saline during 5 days and treated with gallic acid (GA, 13.5 mg/Kg, p.o., daily), EDTA (110 mg/Kg, i.p., daily) or water (10 mL/Kg, p.o.) during 3 days.Table 1GROUPBody weight variation (%) Pb-exposure EndBody weight variation (%) Treatments EndC+4.1 ± 1.1+7.9 ± 1.8GA+3.8 ± 1.6+6.0 ± 1.9Pb−17.5 ± 1.2[\*\*](#tblfn0005){ref-type="table-fn"}−19.4 ± 2.9[\*\*](#tblfn0005){ref-type="table-fn"}PbGA−14.8 ± 3.9[\*\*](#tblfn0005){ref-type="table-fn"}^,^[°](#tblfn0015){ref-type="table-fn"}−12.2 ± 4.1[\*\*](#tblfn0005){ref-type="table-fn"}^,^[\#](#tblfn0010){ref-type="table-fn"}^,^[°°](#tblfn0020){ref-type="table-fn"}PbEDTA−15.8 ± 1.6[\*\*](#tblfn0005){ref-type="table-fn"}−13.4 ± 2.6[\*\*](#tblfn0005){ref-type="table-fn"}[^1][^2][^3][^4][^5]

*The results of Pb exposure and GA and EDTA treatments on hematocrit levels and ALA-D activity are show in* [Table 2](#tbl0010){ref-type="table"}. It was observed a decrease in hematocrit levels (9.6%) in Pb exposed animals in relation to the controls; and this effect was not reversed by any treatment employed (GA or EDTA) \[F(4,30) = 7.26; *P* \< 0.001\]. Pb exposure also decreased blood ALA-D activity in relation to control group (5 times). GA alone had no effects on this variable, but the co-treatments Pb plus GA and Pb plus EDTA partially reversed the effects of Pb on the ALA-D activity. Comparing these two treatments, EDTA reversed the ALA-D activity more effectively than GA did, whose values differed significantly \[F(4,30) = 76.35; *P* \< 0.001\].Table 2Hematocrit and ALA-D activity of rats exposed to Pb (50 mg/Kg, i.p., daily) or saline during 5 days and treated with gallic acid (GA, 13.5 mg/Kg, p.o., daily), EDTA (110 mg/Kg, i.p., daily) or water (10 mL/Kg, p.o.) during 3 days.Table 2GROUPCGAPbPbGAPbEDTAHematocrit41.5 ± 0.841.2 ± 0.637.5 ± 1.6[\*](#tblfn0025){ref-type="table-fn"}36.0 ± 0.3[\*\*](#tblfn0030){ref-type="table-fn"}^,^[°](#tblfn0050){ref-type="table-fn"}37.6 ± 0.6[\*](#tblfn0025){ref-type="table-fn"}ALA-D543.3 ± 24.9568.3 ± 26.9107.8 ± 6.6[\*\*](#tblfn0030){ref-type="table-fn"}303.8 ± 7.0[\*\*](#tblfn0030){ref-type="table-fn"}^,^[-](#tblfn0040){ref-type="table-fn"}^,^[+](#tblfn0045){ref-type="table-fn"}^,^[°](#tblfn0050){ref-type="table-fn"}301.7 ± 26.3[\*\*](#tblfn0030){ref-type="table-fn"}^,^[\#](#tblfn0035){ref-type="table-fn"}[^6][^7][^8][^9][^10][^11][^12]

*The results of Pb exposure and GA and EDTA treatments in blood, liver and kidney oxidative stress parameters and liver damage parameters are show in* [Table 3](#tbl0015){ref-type="table"}. Pb exposure increased TBARS levels in erythrocytes (48.6%) and plasma (42.7%) when compared to the control group \[F(4,30) = 8.11 and F(3,30) = 12.53, respectively, *P* \< 0.001\]. These effects were completely reversed by the treatment with GA. The EDTA treatment partially reversed the TBARS erythrocytes levels in erythrocytes, but no changed plasma TBARS levels in relation to Pb group. In tissues, Pb exposure also increased TBARS levels (35.2% in liver and 47.1% in kidney) in relation to the control group; GA and EDTA treatments reverted its partially in liver and completely in kidney \[F(3,30) = 11.13 and F(3,30) = 15.78, respectively; *P* \< 0.001\].Table 3Oxidative stress parameters in blood, liver and kidney and plasma aminotransferases of rats exposed to Pb (50 mg/Kg, i.p., daily) or saline during 5 days and treated with gallic acid (GA, 13.5 mg/Kg, p.o., daily), EDTA (110 mg/Kg, i.p., daily) or water (10 mL/Kg, p.o.) during 3 days.Table 3GROUPCGAPbPbGAPbEDTATBARSErythrocytes17.88 ± 0.7719.25 ± 1.6926.57 ± 1.68[\*\*](#tblfn0060){ref-type="table-fn"}17.05 ± 1.03[-](#tblfn0070){ref-type="table-fn"}^,^[+](#tblfn0075){ref-type="table-fn"}22.23 ± 1.20[\*](#tblfn0055){ref-type="table-fn"}^,^[\#](#tblfn0065){ref-type="table-fn"}Plasma12.42 ± 0.5113.61 ± 0.6817.73 ± 0.37[\*\*](#tblfn0060){ref-type="table-fn"}12.84 ± 0.75[-](#tblfn0070){ref-type="table-fn"}^,^[++](#tblfn0080){ref-type="table-fn"}17.45 ± 1.10[\*\*](#tblfn0060){ref-type="table-fn"}Liver18.6 ± 0.818.1 ± 1.125.2 ± 1.2[\*](#tblfn0055){ref-type="table-fn"}13.8 ± 1.0[\*](#tblfn0055){ref-type="table-fn"}^,^[-](#tblfn0070){ref-type="table-fn"}13.8 ± 2.3[\*](#tblfn0055){ref-type="table-fn"}^,^[-](#tblfn0070){ref-type="table-fn"}Kidney25.7 ± 0.922.6 ± 0.637.8 ± 1.7[\*\*](#tblfn0060){ref-type="table-fn"}28.7 ± 1.9[-](#tblfn0070){ref-type="table-fn"}24.9 ± 2.0[-](#tblfn0070){ref-type="table-fn"}  CARBONYLLiver2042.6 ± 235.72247.8 ± 115.03153.1 ± 191.4[\*\*](#tblfn0060){ref-type="table-fn"}1862.3 ± 150.1[-](#tblfn0070){ref-type="table-fn"}^,^[+](#tblfn0075){ref-type="table-fn"}2798.2 ± 184.8[\*](#tblfn0055){ref-type="table-fn"}Kidney2209.3 ± 98.62020.7 ± 178.33664.7 ± 533.9[\*\*](#tblfn0060){ref-type="table-fn"}1770.9 ± 95.8[-](#tblfn0070){ref-type="table-fn"}1432.7 ± 170.3[\*](#tblfn0055){ref-type="table-fn"}^,^[-](#tblfn0070){ref-type="table-fn"}  ASTPlasma21.4 ± 0.421.5 ± 0.427.2 ± 0.6[\*\*](#tblfn0060){ref-type="table-fn"}25.5 ± 0.2[\*\*](#tblfn0060){ref-type="table-fn"}^,^[\#](#tblfn0065){ref-type="table-fn"}^,^[°](#tblfn0085){ref-type="table-fn"}24.3 ± 0.7[\*\*](#tblfn0060){ref-type="table-fn"}^,^[-](#tblfn0070){ref-type="table-fn"}ALTPlasma19.2 ± 0.519.6 ± 0.318.2 ± 0.418.1 ± 0.518.4 ± 0.3[^13][^14][^15][^16][^17][^18][^19][^20]

Pb exposure increased carbonyl levels in liver (54.4%) and kidney (65.8%) in relation to control group \[F(3,30) = 8.50 and F(3,30) = 14.22, respectively; *P* \< 0.001\]. GA was able to reverse completely these alterations, but EDTA just partially in kidney and no in liver.

In addition, an increase of AST levels in Pb exposed animals in relation to control group was observed (27.1%) \[F(3,30) = 24.36, *P* \< 0.001\]. This effect was partially reverted by GA and EDTA treatments. No alterations were found in ALT levels.

*The results of Pb exposure and GA and EDTA treatments in antioxidant parameters are show in* [Table 4](#tbl0020){ref-type="table"}. SOD activity was decreased in liver and kidney of Pb exposed animals in relation to the control group (18.5% and 40%, respectively) and these events were partially reverted in liver by GA and EDTA treatments and completely in kidney just by GA treatment.Table 4Antioxidant parameters in blood, liver and kidney of rats exposed to Pb (50 mg/Kg, i.p., daily) or saline during 5 days and treated with gallic acid (GA, 13.5 mg/Kg, p.o., daily), EDTA (110 mg/Kg, i.p., daily) or water (10 mL/Kg, p.o.) during 3 days.Table 4GROUPCGAPbPbGAPbEDTASODLiver2.7 ± 0.12.8 ± 0.12.2 ± 0.1[\*](#tblfn0090){ref-type="table-fn"}2.5 ± 0.12.4 ± 0.2Kidney1.4 ± 0.11.5 ± 0.11.0 ± 0.1[\*](#tblfn0090){ref-type="table-fn"}1.4 ± 0.1[\#](#tblfn0100){ref-type="table-fn"}1.3 ± 0.1  CATErythrocyte26.1 ± 1.028.9 ± 1.324.4 ± 1.231.3 ± 0.9[\*](#tblfn0090){ref-type="table-fn"}^,^[-](#tblfn0105){ref-type="table-fn"}28.2 ± 2.4Liver3017.4 ± 178.32917.8 ± 87.32284.0 ± 202.8[\*](#tblfn0090){ref-type="table-fn"}2837.4 ± 222.1[\#](#tblfn0100){ref-type="table-fn"}2470.3 ± 137.5[\*](#tblfn0090){ref-type="table-fn"}Kidney1354.0 ± 39.71349.4 ± 15.51475.4 ± 90.71518.5 ± 22.71468.9 ± 61.3  GSHErythrocyte2664.5 ± 121.52687.1 ± 124.52913.0 ± 44.22547.9 ± 67.82844.6 ± 209.5Liver8.9 ± 0.48.8 ± 0.65.2 ± 0.8[\*\*](#tblfn0095){ref-type="table-fn"}8.4 ± 0.5[-](#tblfn0105){ref-type="table-fn"}6.9 ± 0.3[\*](#tblfn0090){ref-type="table-fn"}^,^[\#](#tblfn0100){ref-type="table-fn"}Kidney4.3 ± 0.33.8 ± 0.43.9 ± 0.43.2 ± 0.54.4 ± 0.8  VIT. CPlasma19.3 ± 0.419.3 ± 1.119.2 ± 2.122.4 ± 0.521.7 ± 1.6[^21][^22][^23][^24][^25]

It was observed changes in erythrocyte CAT activity just in Pb exposed animals treated with GA (PbGA group) in relation to control group (increase of 19.9%) \[F(3,30) = 3.11, *P* \< 0.05). In liver, CAT activity decreased in Pb-exposed animals in relation to control group (24.3%), and this effect was completely reversed by GA treatment \[F(3,30) = 3.40, P \< 0.05\]. No changes were observed in kidney CAT activity.

GSH levels were decreased in liver of Pb exposed animals in relation to control group (41.5%) \[F(3,30) = 7.65, *P* \< 0.001\]. GA treatment reversed completely this effect and EDTA treatment, partially. No changes were observed in erythrocytes and kidney GSH levels, as well as in plasma VIT C levels.

*The effects of Pb exposure and GA and EDTA treatments in Pb levels are show in* [Table 5](#tbl0025){ref-type="table"}. It was observed an increase in Pb levels in blood, liver and kidney \[F(4,20) = 2.91, *P* \< 0.05; F(4,20) = 3.55, *P* \< 0.05 and F(4,20) = 68.53, *P* \< 0.001; respectively\] in Pb-exposed animals in relation to control group. This effect was reverted by EDTA treatment and not by GA treatment.Table 5Blood, liver and kidney Pb levels of rats exposed to Pb (50 mg/Kg, i.p., daily) or saline during 5 days and treated with gallic acid (GA, 13.5 mg/Kg, p.o., daily), EDTA (110 mg/Kg, i.p., daily) or water (10 mL/Kg, p.o.) during 3 days.Table 5GROUPCGAPbPbGAPbEDTABlood Pb0.03 ± 0.000.02 ± 0.002.98 ± 1.54[\*](#tblfn0110){ref-type="table-fn"}2.69 ± 0.77[\*](#tblfn0110){ref-type="table-fn"}0.82 ± 0.28Liver PbNDND129.66 ± 48.85[\*](#tblfn0110){ref-type="table-fn"}149.22 ± 57.72[\*](#tblfn0110){ref-type="table-fn"}^,^[°](#tblfn0130){ref-type="table-fn"}89.42 ± 36.56Kidney PbNDND135.60 ± 11.56[\*\*](#tblfn0115){ref-type="table-fn"}161.50 ± 16.94[\*\*](#tblfn0115){ref-type="table-fn"}^,^[++](#tblfn0125){ref-type="table-fn"}37.14 ± 3.17[\*](#tblfn0110){ref-type="table-fn"}^,^[-](#tblfn0120){ref-type="table-fn"}[^26][^27][^28][^29][^30][^31]

Statistical analyses revealed a significant correlation between ALA-D activity and blood Pb levels and hematocrit levels (r = 0.57, *P* \< 0.001 and r = 0.55, *P* \< 0.001, respectively).

4. Discussion {#sec0045}
=============

This study showed that rats treated with Pb decrease the body weight in relation to control animals. This result is in agreement with several studies [@bib0035], [@bib0060], [@bib0115], [@bib0185], [@bib0285], [@bib0320], which suggested that less body weight was due to reduced food consumption via Pb effects on the satiety set-point. After the treatment time, only the animals that received GA showed reversion partial of this less body weight, due probably the improvement of behavior and biochemical parameters.

Anemia observed in this study in Pb-exposed animals by decrease in hematocrit can be result by Pb property of inhibit many stages in the heme synthesis, while, for example, the enzyme δ-aminolevulinic acid dehydratase (ALA-D). ALA-D catalyses the formation of porphobilinogen from δ-aminolevulinic acid (ALA) [@bib0100] and it is used as one of the most reliable indicators of Pb intoxication [@bib0175], [@bib0235]. In the present study, this enzyme was reduced in Pb-treated animals, as well as showed negative correlation to Pb blood levels and positive correlation to hematocrit, proving the involving between Pb, ALA-D and hematocrit. However, the GA and EDTA treatments reverted partially the ALA-D inhibition but not restored hematocrit levels, probably because the Pb also shortening of erythrocyte life span due the direct toxic effect of Pb upon the cell membrane [@bib0135] and is required about 3 months for regeneration of circulating erythrocytes.

OS has been involved in Pb toxicity [@bib0085], [@bib0195]. According, the Pb may cause OS by two separate, although related, pathways: (1) the generation of ROS, including hydroperoxides, singlet oxygen, and hydrogen peroxide, and (2) the depletion of antioxidant reserves [@bib0070]. These events were observed in the present study.

The increase in ROS generation can be induced by Pb at different levels: (i) the Pb-induced inhibition of ALA-D may lead to accumulation of its substrate ALA, which can oxidize, and (ii) Pb per se has the capacity to stimulate ferrous ion [@bib0015], [@bib0020], [@bib0105]. In the present study, the oxidative damages caused by ROS can be observed by the increase in lipid peroxidation (TBARS levels) in erythrocytes, plasma, liver and kidney and protein oxidation (carbonyl levels) in liver and kidney in Pb-exposed animals, confirming previous studies [@bib0045], [@bib0280], [@bib0290], [@bib0295], [@bib0320]. Moreover, Pande et al. [@bib0230] did the same our Pb treatment protocol and observed increase in lipid peroxidation in liver. Whereas, GA markedly reversed Pb-induced OS damages, and EDTA too, but EDTA was less effective than GA. Reckziegel et al. [@bib0265] observed similar results in brain of rats treated with Pb and GA. Furthermore, aminotransferases (AST and ALT) represent enzymes that are regarded as markers of liver injury. In this study it was observed a modest increase in plasma AST levels, besides it is not biologically significant for liver injury, which was partially reverted by GA and EDTA treatments.

The antioxidant potential of the body can be enzymatic and non-enzymatic. The antioxidant enzymes evaluated, SOD and CAT, form the first line of defense against ROS and the decrease in their activities contribute to the OS [@bib0025]. Pb reduced the activity of SOD in liver and kidney and of CAT in liver. Interestingly, GA could markedly renew the activities of these antioxidant enzymes of Pb-exposed rats and significantly enhanced the antioxidant capacity of the body. In erythrocytes, GA increased the CAT activity probably as a compensatory mechanism to eliminate hydroperoxides produce during Pb exposure.

GSH is a tripeptide containing cysteine that has a reactive thiol group with reductive potency and can act as a non-enzymatic antioxidant by direct interaction of thiol group with ROS. Pb binds exclusively to the thiol groups which decrease the GSH levels thereby interfering with the antioxidant activity [@bib0310]. In this study, GSH levels decreased in liver only and the treatment with GA reverted completely this decrease and with EDTA, partially. It was observed that liver was the tissue with antioxidant potential most affected by Pb, probably by its involvement in Pb detoxification. Surprisingly, other non-enzymatic antioxidant evaluated, the VIT C, a low molecular mass antioxidant that scavenges the aqueous free radicals, no change in plasma.

Certainly the higher concentration of Pb in blood and tissues, following experimental exposure, was associated with increased oxidative reaction, which might be responsible, at least in part, for Pb-induced toxic effects. In the present study, it was observed an increase in Pb concentrations in blood, liver and kidney in Pb-exposed animals in relation to the control ones. We observed that EDTA, a conventional chelating agent which is used in Pb poisonings, was able to reverse the high Pb concentrations in all structures evaluated, proving it chelating property. In according, Patra et al. [@bib0240] found a significant higher level of Pb in liver of rats exposed to Pb for 4 weeks and a significant reduction of Pb levels after treatment with EDTA during fifth week. However, besides its proved chelating property, we observed that EDTA cannot reverse effectively the antioxidants parameters changed by Pb (SOD and CAT activities and GSH levels). In this sense, we believed that EDTA oxidative protection, observed in TBARS and carbonyl levels, can be due the chelating action, which decrease Pb body concentrations. On the other hand, GA no decreased body Pb concentrations, but reverted oxidative parameters and antioxidants alterations. This results show that GA reversion in oxidative damages induced by Pb cannot be attributed by chelating property while EDTA, but to its antioxidant potential and capacity of improve the body antioxidant defenses.

Data from literature showed that GA antioxidant property proven here is due its capacity to scavenge ROS, like superoxide anions, hydrogen peroxide, hydroxyl radicals and hypochlorous acid [@bib0130], [@bib0255]. Its molecular structure has tri-hydroxyl groups, thereby verifying a previous report that phenolic hydroxyl groups are important in showing a potent radical scavenging effect [@bib0315]. Lu et al. [@bib0165] showed that the hydroxyl group at the *para* position to the carboxylic group is especially effectual for GA antioxidant activity ([Fig. 1](#fig0005){ref-type="fig"}).

5. Conclusion {#sec0050}
=============

GA is able to reverse oxidative damages induced by Pb due it antioxidant potential and capacity of improve body antioxidant status and not by chelating property. In addition, the results showed here confirm the beneficial of antioxidants use in Pb intoxications. Further studies are needed to evaluate the use of GA together of a chelating agent in Pb-treated rats.

[^1]: Body weights in sixth and ninth days were expressed in relation to the initial weight. Data are expressed as mean ± S.E.M.

[^2]: difference from C group (*P* \< 0.001).

[^3]: difference from Pb group (*P* \< 0.05).

[^4]: difference from GA group (P \< 0.05).

[^5]: difference from GA group (*P* \< 0.001).

[^6]: ALA-D activity (nmol PBG/h/mL blood). Data are expressed as mean ± S.E.M.

[^7]: difference from C group (*P* \< 0.05).

[^8]: difference from C group (*P* \< 0.001).

[^9]: difference from Pb group (*P* \< 0.05).

[^10]: difference from Pb group (*P* \< 0.001).

[^11]: difference from PbEDTA group (*P* \< 0.05).

[^12]: difference from GA group (*P* \< 0.05).

[^13]: TBARS levels (nmol MDA/g tissue); protein carbonyl levels (nmol protein carbonyl/g tissue). Data are expressed as mean ± S.E.M.

[^14]: difference from C group (*P* \< 0.05).

[^15]: difference from C group (*P* \< 0.001).

[^16]: difference from Pb group (*P* \< 0.05).

[^17]: difference from Pb group (*P* \< 0.001).

[^18]: difference from PbEDTA group (*P* \< 0.05).

[^19]: difference from PbEDTA group (*P* \< 0.001).

[^20]: difference from GA group (*P* \< 0.05).

[^21]: SOD activity (U/g of tissue); CAT activity (μmol H~2~O~2~/min/mL erythrocytes or μmol H~2~O~2~/min/g tissue); GSH levels (nmol GSH/mL erythrocytes or mmol GSH/g tissue); plasma VIT C levels (mg VIT C/mL plasma). Data are expressed as mean ± S.E.M.

[^22]: difference from C group (*P* \< 0.05).

[^23]: difference from C group (*P* \< 0.001).

[^24]: difference from Pb group (*P* \< 0.05).

[^25]: difference from Pb group (*P* \< 0.001).

[^26]: Lead levels (ppm). ND (no detectable, levels below 0.2 ppm). Data are expressed as mean ± S.E.M.

[^27]: difference from C group (*P* \< 0.05).

[^28]: difference from C group (*P* \< 0.001).

[^29]: difference from Pb group (*P* \< 0.001).

[^30]: difference from PbEDTA group (*P* \< 0.001).

[^31]: difference from GA group (*P* \< 0.05).
